Universal Ibogaine announces partners for clinical trial using ibogaine in opioid use disorder

Universal Ibogaine CEO Nick Karos joined Steve Darling from Proactive to share news the company has chosen their partners for its planned clinical trial in Canada to be conducted, subject to the required approval by Health Canada. Karos telling Proactive Intrinsik Corp who is an internationally recognized regulatory affairs consulting firm will provide regulatory strategy and support for the preparation and submission of UI’s Canadian Clinical Trial Application. The group has over 25 regulatory affairs professionals based in its Canadian headquarters located in Toronto.

The company also announced CATO Research Canada as well. The CATO team of experts has over 30-years of experience optimizing the design and execution of clinical trials. They have successfully conducted over 500 clinical trials in over 25 countries and have enrolled more than 60,000 patients at over 5,500 sites. Karos said the group is finalizing the study design in advance of an anticipated pre-clinical trial application meeting to soon be held with Health Canada.

Story by ProactiveInvestors